Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGTXNASDAQ:CRVONASDAQ:GNTANASDAQ:OCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$0.32+7.9%$0.34$0.22▼$2.54$19.96M0.752.72 million shs1.04 million shsCRVOCervoMed$7.20+1.1%$8.64$1.80▼$22.57$62.97M-0.731.34 million shs102,775 shsGNTAGenenta Science$3.61-7.1%$4.12$2.79▼$7.28$65.94M0.7315,007 shs13,485 shsOCXOncoCyte$2.77+4.7%$2.97$1.92▼$4.75$77.93M0.9758,822 shs39,025 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics0.00%+1.02%-8.27%-33.25%-86.25%CRVOCervoMed0.00%-6.56%-18.91%-21.33%-62.55%GNTAGenenta Science0.00%-22.65%-8.82%-0.26%+19.70%OCXOncoCyte0.00%-10.77%-5.02%-28.38%-3.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGTXCognition Therapeutics3.6576 of 5 stars3.55.00.00.03.01.71.3CRVOCervoMed3.2329 of 5 stars3.45.00.00.02.71.70.6GNTAGenenta Science2.8071 of 5 stars3.55.00.00.02.21.70.0OCXOncoCyte2.823 of 5 stars3.44.00.00.03.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics 3.00Buy$5.631,646.89% UpsideCRVOCervoMed 2.89Moderate Buy$27.63283.68% UpsideGNTAGenenta Science 3.00Buy$25.00593.48% UpsideOCXOncoCyte 2.75Moderate Buy$6.06118.55% UpsideCurrent Analyst Ratings BreakdownLatest CGTX, OCX, GNTA, and CRVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/27/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.005/21/2025OCXOncoCyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/21/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.005/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/13/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.255/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.005/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.004/8/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.253/28/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.003/26/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/ACRVOCervoMed$7.14M8.78N/AN/A$1.30 per share5.54GNTAGenenta ScienceN/AN/AN/AN/A$1.21 per shareN/AOCXOncoCyte$3.84M20.64N/AN/A$2.48 per share1.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$25.79M-$0.74N/AN/AN/AN/A-150.93%-100.82%8/6/2025 (Estimated)CRVOCervoMed-$2.17M-$2.18N/AN/AN/A-118.68%-44.11%-39.81%8/8/2025 (Estimated)GNTAGenenta Science-$12.60MN/A0.00N/AN/AN/AN/AN/AN/AOCXOncoCyte-$27.78M-$3.53N/AN/AN/A-6,122.29%-269.32%-59.71%8/6/2025 (Estimated)Latest CGTX, OCX, GNTA, and CRVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million5/12/2025Q1 2025OCXOncoCyte-$0.24-$0.26-$0.02-$0.26$0.13 million$2.14 million5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12-$0.14-$0.02-$0.14N/AN/A3/24/2025Q4 2024OCXOncoCyte-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 million3/20/2025Q4 2024CGTXCognition Therapeutics-$0.16-$0.17-$0.01-$0.17N/AN/A3/17/2025Q4 2024CRVOCervoMed-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A2.112.11CRVOCervoMedN/A15.0415.04GNTAGenenta ScienceN/A9.31N/AOCXOncoCyteN/A0.530.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%CRVOCervoMed25.15%GNTAGenenta Science15.13%OCXOncoCyte55.35%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics14.40%CRVOCervoMed35.40%GNTAGenenta Science28.99%OCXOncoCyte2.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2061.99 million32.93 millionNot OptionableCRVOCervoMed48.70 million3.93 millionNot OptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableOCXOncoCyte12028.60 million17.18 millionNo DataCGTX, OCX, GNTA, and CRVO HeadlinesRecent News About These CompaniesAWM Investment Company Inc. Has $1.85 Million Position in OncoCyte Co. (NASDAQ:OCX)May 23, 2025 | marketbeat.comOncocyte Corp. Adjusts Pricing for GraftAssureCore™ Assay to $2,753, Enhancing Market Opportunities and Reimbursement PotentialMay 21, 2025 | nasdaq.comOncocyte Corporation: Medicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 20, 2025 | finanznachrichten.deMedicare Boosts Reimbursement for Oncocyte’s Flagship TechnologyMay 19, 2025 | finance.yahoo.comMedicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 19, 2025 | globenewswire.comOncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business ProgressMay 13, 2025 | finanznachrichten.deOncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiativeMay 13, 2025 | msn.comOncoCyte Corporation (OCX) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comOncocyte Reports Q1 2025 Results and Business ProgressMay 12, 2025 | globenewswire.comOncoCyte Q1 2025 Earnings PreviewMay 11, 2025 | msn.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7, 2025 | globenewswire.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7, 2025 | prismmediawire.comWhy OncoCyte Corporation’s (OCX) Stock Is Up 5.11%May 7, 2025 | aaii.comBest Momentum Stocks to Buy for May 6thMay 6, 2025 | zacks.comNew Strong Buy Stocks for May 6thMay 6, 2025 | zacks.comOncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | finanznachrichten.deOncocyte study links blood test to kidney rejection markersApril 30, 2025 | investing.comOncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | globenewswire.comOncocyte’s Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | taiwannews.com.twOncocyte's Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | globenewswire.comWhy OncoCyte Corporation’s (OCX) Stock Is Up 12.22%April 25, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGTX, OCX, GNTA, and CRVO Company DescriptionsCognition Therapeutics NASDAQ:CGTX$0.32 +0.02 (+7.95%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.CervoMed NASDAQ:CRVO$7.20 +0.08 (+1.12%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Genenta Science NASDAQ:GNTA$3.60 -0.28 (-7.09%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.OncoCyte NASDAQ:OCX$2.77 +0.12 (+4.68%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
